Publications by authors named "Dirk Thomas"

Claim this Profile
T
The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial.
Ron T Gansevoort, David C Wheeler, Francisco Martínez Debén, Marijn Speeckaert, Dirk Thomas

Nephrol Dial Transplant· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New Generation of sGC Stimulators: Discovery of Imidazo[1,2-]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension.
Alexandros Vakalopoulos, Frank Wunder, Ingo V Hartung, Gorden Redlich, Rolf Jautelat, Thomas Mondritzki, Dirk Thomas

J Med Chem· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men.
Bettina Nowotny, Dirk Thomas, Stephan Schwers, Sara Wiegmann, Wolfgang Prange

J Thromb Haemost· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa.
Dirk Thomas, Friederike Kanefendt, Stephan Schwers, Sigrun Unger, Ashraf Yassen

J Thromb Haemost· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.
Michael Boettcher, Dirk Thomas, Wolfgang Mueck, Stephanie Loewen, Erich Arens

Eur J Clin Pharmacol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies.
Michael Boettcher, Michael Gerisch, Maximilian Lobmeyer, Nina Besche, Dirk Thomas

Clin Pharmacokinet· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of bioequivalence, safety, and tolerability of a fixed-dose combination of nifedipine GITS and candesartan compared with the corresponding loose-dose combination under fed conditions
.
Dirk Thomas, Yuwang Liu, Herbert Stein, Boris Weimann

Int J Clin Pharmacol Ther· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics.
Dirk Thomas, Kirstin Thelen, Stefanie Kraff, Stephan Schwers, Sonja Schiffer

Res Pract Thromb Haemost· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic interaction of riociguat with ketoconazole, clarithromycin, and midazolam.
Corina Becker, Reiner Frey, Sigrun Unger, Dirk Thomas, Michael Reber

Pulm Circ· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of bioequivalence of a new fixed-dose combination of nifedipine and candesartan with the corresponding loose combination as well as the drug-drug interaction potential between both drugs under fasting conditions.
Erich Brendel, Boris Weimann, Hartmut Dietrich, Christoph Froede, Dirk Thomas

Int J Clin Pharmacol Ther· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lacosamide.
Pamela Doty, G David Rudd, Thomas Stoehr, Dirk Thomas

Neurotherapeutics· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability.
Joachim Seybold, Dirk Thomas, Martin Witzenrath, Sengül Boral, Andreas C Hocke

Blood· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis